Dr Mo Yin
Contact information
Research groups
Mo Yin
Honorary Visiting Research Fellow
- Infectious Diseases Physician
Bacterial Resistance Analysis Group
Dr Mo Yin is a highly motivated Infectious Diseases physician driven by the ideal of using quality clinical research to influence patient care and propel health policies. She has been active in epidemiological and clinical research, medical education, as well as hospital administration. She has received numerous awards for her achievements in clinical care, research and teaching. Dr Mo Yin’s career goal is to serve her community focusing on translational research to influence regional and global policies.
She is completed a DPhil in Clinical Medicine in 2022, during which she led a multi-centre randomised control trial to assess the impact of shortening treatment duration for ventilator-associated pneumonia.
Dr Mo Yin is currently the deputy director for the ADVANCE-ID research network, which focuses on conducting innovative and pragmatic large-scale randomised controlled trials for diagnosing and treating multidrug-resistant bacterial infections.
Recent publications
-
Informed consent and risk communication challenges in antimicrobial clinical trials: a scoping review.
Journal article
Shou Y. et al, (2024), BMJ Open, 14
-
Concerning the use of aminoglycosides in ventilator-associated pneumonia - Authors' reply.
Journal article
Chhabra S. and Mo Y., (2024), The Lancet. Respiratory medicine, 12
-
Individualised, short-course antibiotic treatment versus usual long-course treatment for ventilator-associated pneumonia (REGARD-VAP): a multicentre, individually randomised, open-label, non-inferiority trial.
Journal article
Mo Y. et al, (2024), The Lancet. Respiratory medicine, 12, 399 - 408
-
Win ratio analyses of piperacillin-tazobactam versus meropenem for ceftriaxone non-susceptible Escherichia coli or Klebsiella pneumoniae bloodstream infections: Post-hoc insights from the MERINO trial.
Journal article
Hardy M. et al, (2024), Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
-
Study protocol: infectious diseases consortium (I3D) for study on integrated and innovative approaches for management of respiratory infections: respiratory infections research and outcome study (RESPIRO).
Journal article
Ng DHL. et al, (2024), BMC infectious diseases, 24